Disclosed herein are automated processes and systems for determining an underlying cause of anemia. Also disclosed herein are processes and systems for determining an underlying cause of microcytic anemia, normocytic anemia, and macrocytic anemia. Additionally disclosed herein are methods of treating the underlying cause of anemia in an individual in need thereof.

Methods and compositions for treatment of paroxysmal nocturnal hemoglobinuria are described. In some aspects, the disclosure features a method of treating a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising subcuta-neously administering to the subject pegcetacoplan.

Provided are an anti-CD73-anti-PD-1 bispecific antibody, a pharmaceutical composition thereof and a use thereof.

A method of predicting whether an MDS patient has a good or poor prognosis uses a general purpose computer configured as a classifier and mass-spectrometry data obtained from a blood-based sample. The classifier assigns a classification label of either Early or Late (or the equivalent) to the patient's sample. Patients classified as Early are predicted to have a poor prognosis or worse survival whereas those patients classified as Late are predicted to have a relatively better prognosis and longer survival time. The groupings demonstrated a large effect size between groups in Kaplan-Meier analysis of survival. Most importantly, while the classifications generated were correlated with other prognostic factors, such as IPSS score and genetic category, multivariate and subgroup analysis showed that they had significant independent prognostic power complementary to the existing prognostic factors.

The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.

The present invention relates to a kit for quantitative analysis of glycated hemoglobin (HbA1c), and the kit for quantitative analysis of HbA1c according to the present invention has excellent long-term stability of an enzyme reagent and thus has an effect of easily overcoming the disadvantages of the conventional reagents used in enzyme assays (e.g., storage, accuracy, portability, convenience of use, etc.).

The disclosure relates to bispecific antibodies against CD3c and BCMA for use in the treatment of diseases. The disclosure provides methods of determining the responsiveness of a patient to such treatment and relates to diagnostic assays.

The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.

An imaging system for imaging a fluid sample includes a light source configured to generate a beam of light, an angled element disposed along an optical path of the beam of light, and a sample cartridge holder configured to receive a sample cartridge and configured to hold the sample cartridge in a first position in which an imaging region of the sample cartridge is disposed along the optical path. The system further includes a sensor configured to capture the beam of light after it passes through the angled element and the imaging region of the sample cartridge. The imaging region of the sample cartridge is configured to receive the sample fluid. A sample cartridge having a cover plate and a fluidics layer is also disclosed. The fluidics layer includes an opening, a fluid channel, and an imaging region configured to receive a whole blood sample.

Lower iron in blood can be accomplished by checking iron level in blood and taking daily an amount of Psyllium husk predetermined to be effective in reducing iron level in blood. Iron level is monitored. Daily intake of Psyllium husk is stopped or significantly reduced when iron level in blood is detected to be at a desired level.